Skip to main content

CSL

Company Profile
csl
Enterprise Value: US$91.7 bn
Region: Asia Pacific
Theme:
Health
Website: csl.com/

Sub-theme: Pharmaceutical therapies

CSL develops medical products for serious and life-threatening diseases. Its core business is as a provider of human blood plasma-derived products to treat bleeding disorders, rare and serious infections and autoimmune diseases. CSL also manufactures vaccines and related products, including for flu and cervical cancer, as well as other products that speed up recovery times for patients that have undergone heart surgery, organ transplants and burns. The company provides these solutions across North America, Europe, Asia, Australia as well as other parts of the world.

Impact Score: 35%

In many cases CSL’s blood plasma products are lifesaving and the company’s vaccines play a critical role in preventing illness. The company has a large market and provides a number of unique therapies to vulnerable communities around the world.

Fundamental Quality: 74%

CSL is a high quality operator of a blood plasma collection network as well as therapy manufacturing facilities. The company has a strong track-record of acquiring and improving businesses and a strong pipeline of therapies. ESG performance and disclosure is solid.

Link to UN SDGs SDG 3
CSL’s products address major global disease burdens like influenza as well as life-threatening conditions like haemophilia and are aligned with SDG 3.
Learn more
Impact calculator metric
(per £1m invested)
Health:
78 people with healthier lives and improved well-being
Recent stewardship topics
  • Ethical issues associated with blood donations
Learn more
Negative impacts
  • Side-effects from pharmaceuticals
  • Product pricing restricts access for poor communities
  • Plastic waste from packaging
  • Animal testing of pharmaceuticals
Related

Sign up to impact fund updates

Sign up below to receive email updates on our impact investment funds.
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
Authorised and regulated by the Financial Conduct Authority Copyright 2024© WHEB. All rights reserved Made by Thursday